Neramexane Formulation for NMDA-Mediated Hearing Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hearing loss, particularly tinnitus, lack effective pharmaceutical solutions that address the complex etiology of hearing impairment and noise-induced damage, with existing drugs having limited efficacy and potential side effects.
Innovation Solution
Neramexane or its pharmaceutically acceptable salt, administered in various dosages and formulations, acts as an NMDA receptor antagonist to alleviate hearing loss symptoms by blocking excitotoxic effects, potentially combined with other pharmaceutical agents for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drugs are used for treating hearing loss, then treatment is provided, but efficacy is limited and side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of 1-amino-alkylcyclohexane compounds to optimize their pharmacological properties. Specific substitutions at positions 2, 4, and 6 of the cyclohexane ring, along with variations in amino group substituents, are designed to enhance NMDA receptor antagonism while reducing ototoxicity and other side effects associated with existing hearing loss treatments
Solution Approach 2:
The patent employs composite material principles by creating complex molecular structures that combine multiple functional groups within the 1-amino-alkylcyclohexane framework. These composite structures integrate NMDA receptor binding moieties with modified stereochemical configurations to achieve selective neuroprotection in the inner ear while minimizing systemic side effects
2Reliability
If NMDA receptor antagonists are used, then excitotoxic effects are blocked, but selectivity for inner ear protection is required
Solution Approach 1:
The patent applies local quality by designing compounds with specific stereochemical configurations and substituent patterns that confer selective affinity for NMDA receptors in the inner ear. The modified 1-amino-alkylcyclohexane structures are engineered to preferentially accumulate in or act upon cochlear neurons, providing localized neuroprotection while sparing other neural tissues from unnecessary drug exposure
Solution Approach 2:
The patent uses intermediary principles by developing compounds that act as selective mediators between glutamate and NMDA receptors in the inner ear. The 1-amino-alkylcyclohexane derivatives serve as intermediate structures that modulate receptor activity with optimized binding kinetics, providing protective effects during acoustic trauma while allowing normal physiological glutamate signaling in other brain regions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Neramexane demonstrates improvement in hearing thresholds and symptom relief for patients with mild to severe hearing loss, including tinnitus, through its modified release formulations and combination therapies, as shown in clinical trials.
Implementation Method 1
neramexane appears to be a low to moderate-affinity, non-competitive NMDA-receptor antagonist believed to selectively block the excitotoxic effects associated with abnormal transmission of glutamate
Data Source
Figure 1
AI summary
The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.